CBASS Antiphage Defense: How Bacteria Sense Phages

Key Takeaways

Protease cleavage of CD-NTase activation loops triggers CBASS antiphage defense signaling.
T4 gp21 protease activates the E. coli CdnG CBASS system.
Activation-loop differences influence recognition of different bacteriophages by CBASS.
Protease-sensitive activation loops occur across multiple CD-NTase enzyme groups.

When a bacteriophage infects a bacterium, the outcome is not determined by viral replication alone. Bacteria carry molecular defense systems that can detect an infection and disrupt the phage before it produces new virus particles. These defenses can recognize different signs of phage invasion, interfere with viral replication, or trigger cellular responses that prevent the infection from progressing.

A new study identifies a direct way some Antiphage Defense systems can detect a phage: by sensing proteolytic activity. Rather than recognizing a viral protein through a conventional receptor, the bacterial defense enzyme can contain a protease-sensitive region that acts as a molecular trigger. When that region is cleaved, the enzyme switches into a signaling state. The finding helps explain how bacteria can recognize a particular stage of phage infection and suggests a possible additional consideration for phage selection and engineering: whether a candidate phage activates the intracellular immune systems of its bacterial target.

How CBASS detects phage infection

CBASS, or cyclic oligonucleotide-based antiphage signaling systems, is a bacterial defense mechanism built around cGAS/DncV-like nucleotidyltransferases, known as CD-NTases. When activated, these enzymes produce cyclic nucleotide signals that trigger downstream defenses against phage infection. The study examined whether viral protease activity could provide the trigger.

Using bacteriophage T4 infecting Escherichia coli, the researchers first found that a T4 mutant lacking two anti-CBASS genes, acb1 and acb2, was sensitive to a type II CBASS system. Further experiments implicated the T4 gp21 protease in triggering the defense. The timing was notable. gp21 is a T4 prohead protease, and its activity occurs during the later stages of phage assembly. This suggested that CBASS might be detecting an enzymatic event associated with phage maturation rather than simply recognizing the presence of a phage.

The activation-loop mechanism

The researchers reconstructed the system biochemically using the E. coli CD-NTase CdnG. They found that several proteases, including proteinase K, trypsin, Glu-C and chymotrypsin, could activate CdnG and stimulate production of the cyclic nucleotide signal 3′2′-cGAMP. Protease-dependent activation was reported to be more than 50-fold stronger than previously developed artificial activation conditions.

The researchers then identified a surface-exposed, flexible region of CdnG that appears to function as an activation loop. Their model is that protease cleavage of this loop changes the enzyme into an active signaling state. This gives the defense system a molecular “tripwire.” Instead of needing to identify the invading phage directly, the bacterium can monitor an activity produced by the phage during infection. The mechanism is also conditional: the relevant phage protease has to be compatible with the bacterial sensor. That helps explain why changes in the sensor can alter which phages trigger the defense.

Why different phages can produce different outcomes

Experiments with CdnG variants showed that mutations in the activation loop could alter CBASS recognition of different phages. Some changes weakened defense against T4 while retaining activity against another phage, Bas51. The result suggests that CBASS recognition is not simply a general response to any protease. The molecular compatibility between the activation loop and the protease matters.

The researchers extended their analysis to more than 1,300 CD-NTase enzymes and identified activation-loop architectures across multiple groups. They then experimentally tested 12 representative enzymes. Seven of nine predicted to contain activation loops responded to proteinase K, whereas the three tested enzymes lacking the predicted loops did not. These results support protease-dependent activation as a recurring mechanism in a subset of CBASS systems, rather than demonstrating that every CBASS system uses the same sensing strategy.

A possible application: CBASS-aware phage selection and engineering

The most immediate application suggested by CBASS antiphage defense mechanism is not a new antibiotic. It is a possible additional layer in how therapeutic bacteriophages are evaluated. Phage therapy depends on finding phages capable of infecting a target bacterium, but successful infection requires more than entry. Once inside the cell, a phage encounters bacterial defense systems that can prevent replication.

A 2026 review in Nature Reviews Microbiology emphasizes the importance of rational phage selection and a detailed understanding of bacterial–phage interactions, while noting that successful therapeutic outcomes are difficult to predict from simple in-vitro susceptibility testing alone. The CBASS antiphage defense mechanism suggests one molecular feature that could eventually be incorporated into this process. Researchers could characterize the CBASS systems present in a bacterial strain and determine whether candidate phages activate them. A resulting compatibility profile could connect:

Bacterial CBASS sensor → phage protease → CBASS activation → phage restriction

Such information could complement conventional measurements such as host range and productive infection. It could help distinguish between a phage that can enter a bacterium and one that can complete its intracellular replication program without strongly triggering a relevant defense system.

A longer-term possibility is to investigate whether phages can be selected or engineered to avoid particular intracellular defense mechanisms. Understanding which phage proteases activate which CBASS sensors could therefore become relevant to rational engineering of microbes and phages.

However, this remains a proposed research direction. The study did not demonstrate that modifying a phage protease improves phage-therapy efficacy, nor did it test engineered therapeutic phages in animal or human treatment. Establishing that application would require experiments showing that CBASS-aware selection or engineering produces more productive infection under therapeutically relevant conditions.

What the study establishes

The strongest evidence is at the molecular and cellular levels. The experiments support three main conclusions: proteolytic cleavage of a CD-NTase activation loop can trigger nucleotide immune signaling; the T4 gp21 protease can activate the E. coli CBASS system; and differences in the activation loop can influence recognition of different phages. The broader sequence analysis indicates that related activation-loop architectures occur across many CD-NTases. The findings do not establish that all CBASS antiphage defense systems detect proteases or that every phage protease will activate CBASS antiphage defense.

Phage therapy involves additional barriers, including bacterial resistance, phage adaptation, delivery, pharmacokinetics and interactions with the human host. These factors mean that a molecular mechanism identified in bacterial cells cannot by itself establish therapeutic effectiveness.

There is also a remaining mechanistic question. Although the study identifies activation-loop cleavage as the trigger, the precise structural transition connecting cleavage to catalytic activation remains unresolved. Determining how cleavage changes the enzyme will help establish the complete molecular pathway.

Why the finding matters

The broader significance of the work is that it reveals another way bacterial immunity can recognize a viral infection: by monitoring what the virus does rather than simply detecting what it is. For phage biology, that distinction provides a useful framework for studying how bacteria and phages adapt to one another. For phage engineering, it raises the possibility that intracellular defense compatibility could eventually become an additional parameter when selecting or designing candidate phages.

That possibility still requires experimental validation. However, the study identifies a defined molecular mechanism in which a phage protease interacts with a bacterial CD-NTase activation loop. This mechanism can now be tested as part of future research into phage-host compatibility.

Bottom line

The study identifies protease activity as a trigger for CBASS antiphage immunity in the bacterial systems examined. A protease-sensitive activation loop in certain CD-NTases can act as a molecular tripwire, with cleavage enabling nucleotide immune signaling. The mechanism helps explain how bacteria can detect a later stage of phage infection and why different phages can be recognized differently by related CBASS systems.

For phage therapy, the defensible implication is prospective: CBASS antiphage defense activation could potentially become one component of molecular compatibility testing used to evaluate or engineer phages. Whether that strategy improves phage performance or therapeutic outcomes remains to be established.

FAQs on CBASS Antiphage Defense

Q: How do bacteria protect themselves from bacteriophages?
A: Bacteria have several molecular defense systems that can recognize or interfere with phage infections. These systems can block viral replication, destroy phage components, or activate cellular responses that stop the infection.

Q: Can bacteria become resistant to bacteriophages?
A: Yes. Bacteria can resist phages through multiple defense mechanisms, including systems that detect and disrupt phage infection. CBASS is one example of an antiphage defense system that can contribute to this resistance.

Q: What is phage therapy?
A: Phage therapy uses bacteriophages to target and kill bacterial cells. It is being investigated as a potential approach for treating bacterial infections, particularly as antibiotic resistance becomes a growing concern.

Q: What is CBASS in bacteria?
A: CBASS stands for cyclic oligonucleotide-based antiphage signaling systems. It is a bacterial defense system that can detect phage infection and activate molecular responses that restrict the virus.

Q: Why is CBASS important for phage research?
A: CBASS helps explain how bacteria can recognize and defend against phages after infection begins. Understanding these interactions could eventually help researchers evaluate phage-host compatibility and improve phage selection or engineering.

Q: What is CBASS antiphage immunity and how does it protect bacteria?
A: CBASS, or cyclic oligonucleotide-based antiphage signaling systems, is a bacterial defense mechanism that uses CD-NTase enzymes to produce cyclic nucleotide signals when activated. These signals trigger downstream defenses that can interfere with bacteriophage infection.

Q: How does CBASS antiphage defense detect a bacteriophage infection?
A: The study shows that some CBASS antiphage defense systems can detect phage infection by sensing proteolytic activity rather than directly recognizing a viral protein. Protease cleavage of a flexible activation loop in certain CD-NTases can switch the enzyme into an active signaling state.

Q: How does a phage protease activate the bacterial CBASS antiphage defense system?
A: In the T4 and E. coli system examined, the T4 gp21 protease can cleave a protease-sensitive region of the bacterial CD-NTase CdnG. This cleavage activates CdnG and stimulates production of the cyclic nucleotide signal 3′2′-cGAMP.

Q: Why does the T4 gp21 protease trigger CBASS immunity?
A: T4 gp21 is a prohead protease involved during phage assembly, so its activity provides the bacterium with a molecular signal associated with a later stage of infection. The findings suggest that CBASS can monitor what a phage is doing inside the cell rather than simply detecting that a phage is present.

Q: Can different bacteriophages trigger CBASS in different ways?
A: Yes. Experiments with CdnG variants showed that changes in the CD-NTase activation loop can alter recognition of different phages. This indicates that CBASS recognition depends partly on molecular compatibility between the bacterial sensor and phage proteins such as proteases.

Q: What is a CD-NTase activation loop in CBASS?
A: A CD-NTase activation loop is a flexible, surface-exposed region of certain bacterial immune enzymes that can function as a molecular sensing element. In the mechanism described, protease cleavage of this loop changes the enzyme into an active signaling state.

Q: Could CBASS help researchers select better phages for phage therapy?
A: Potentially, but this has not yet been demonstrated therapeutically. The mechanism suggests that researchers could eventually consider whether a candidate phage activates the CBASS antiphage defense systems present in its bacterial target, alongside conventional measurements such as host range and productive infection.

Q: Can phages be engineered to avoid CBASS antiphage defenses?
A: The study raises this as a possible future direction rather than demonstrating it. Understanding which phage proteases activate specific CBASS sensors could eventually help researchers investigate whether phages can be selected or engineered to reduce activation of particular intracellular defense systems.

Q: Does every CBASS system detect phage proteases?
A: No. The study does not establish that all CBASS antiphage defense systems use protease sensing. Experiments across CD-NTases support protease-dependent activation as a recurring mechanism in a subset of systems, while enzymes without the predicted activation-loop architecture did not respond in the tested experiments.

Q: Does this CBASS discovery prove that phage therapy will work better?
A: No. The research establishes a molecular and cellular mechanism for CBASS antiphage defense activation but does not show that selecting or engineering phages based on this mechanism improves therapeutic outcomes. Animal studies, therapeutic testing, and evaluation of factors such as delivery, resistance and host interactions would be needed to establish that application.

References

Disclaimer:
Some aspects of the preparation of this content may be assisted by artificial intelligence or automated technologies and are subject to human editorial review and source verification. Readers are encouraged to consult the original research and primary sources for complete context. External links are provided for convenience, and TheHonores does not control or endorse their content. Relevant conflicts of interest, funding, sponsorship, or other disclosures are identified where applicable. This content is for informational purposes only and is not professional or medical advice. Images are for illustrative or representational purposes unless otherwise stated. Image credit – Professor Graham Beards, via Wikimedia Commons.